İnterlökin-22 ve Klinik Önemi
Özet
İnterlökin-22 (IL-22) ilk olarak 2000 yılında Dumoutier ve arkadaşları tarafından IL-9 ile uyarılan timik lenfomaların sekretomunda bulunmuştur ve IL-10 sitokin ailesinin bir üyesi olarak sınıflandırılmıştır.
İnterlökin 22 (IL-22) anti-mikrobiyal savunma, homeostaz ve doku onarımında önemli rol oynayan yeni bir sitokindir. IL-22’nin ana kaynağı, Th22 hücreleri, Th1 hücreleri ve Th17 hücreleri dahil olmak üzere CD4+ T hücreleridir yalnız küçük bir kısmı CD8+ T hücrelerinden, natural killer hücrelerden ve doğuştan gelen lenfositlerden oluşur.
IL-22 reseptörü (IL-22R), IL- 22’den gelen sinyallerin iletilmesinden sorumlu olan IL-10R2 ve IL-22R1 olmak üzere iki farklı alt birimden oluşur. IL-22 büyük ölçüde lenfoid hücreler olmak üzere hematopoetik sistem tarafından salgılanan bir sitokin olmasına karşın, IL-22 reseptör kompleksi (IL- 22R) hematopoetik olmayan hücrelerde görülmektedir. Fonksiyonel IL-22R, IL- 22R1 ve IL-10R2’den oluşan bir heterodimerdir. IL-10R2 yaygın olarak eksprese edilirken, IL-22R1’in sadece çeşitli organların (bronş, karaciğer, pankreas ve bağırsak gibi) epidermal hücreler ve stroma hücrelerinde eksprese edildiği düşünülmektedir.
Bağırsak, akciğer, karaciğer, böbrek, timus, pankreas ve deri gibi çeşitli doku ve organlara etki eden IL-22’nin; sedef hastalığı, ülseratif kolit, sistemik lupus eritematozus ve diğer birçok enflamatuvar hastalıkta antienflamatuvar veya proenflamatuvar sitokin görevi görmektedir.
Interleukin-22 (IL-22) was first found in the secretome of IL-9-stimulated thymic lymphomas by Dumoutier et al in 2000 and was classified as a member of the IL-10 cytokine family.
Interleukin 22 (IL-22) is a novel cytokine that plays an important role in antimicrobial defense, homeostasis, and tissue repair. The main source of IL-22 is CD4+ T cells, including Th22 cells, Th1 cells, and Th17 cells, with a small portion consisting of CD8+ T cells, natural killer cells, and innate lymphocytes.
The IL-22 receptor (IL-22R) consists of two different subunits, IL-10R2 and IL-22R1, which are responsible for transmitting signals from IL-22. Although IL-22 is a cytokine secreted by the hematopoietic system, largely by lymphoid cells, the IL-22 receptor complex (IL-22R) is seen on non-hematopoietic cells. Functional IL-22R is a heterodimer consisting of IL-22R1 and IL-10R2. While IL-10R2 is widely expressed, IL-22R1 is thought to be expressed only in epidermal cells and stroma cells of various organs (such as the bronchus, liver, pancreas, and intestine).
IL-22, which affects various tissues and organs such as the intestine, lung, liver, kidney, thymus, pancreas and skin, acts as an anti-inflammatory or pro-inflammatory cytokine in psoriasis, ulcerative colitis, systemic lupus erythematosus and many other inflammatory diseases.
Referanslar
Dumoutier L, Van Roost E, Colau D, Renauld JC. Human interleukin-10-related T cell-derived inducible factor: molecular cloning and functional characterization as an hepatocyte-stimulating factor. Proc. Natl Acad. Sci. USA. 2000; 97:10144–10149
Dumoutier L, Van Roost E, Ameye G, Michaux L, Renauld JC. IL-TIF/IL-22: genomic organization and mapping of the human and mouse genes. Genes Immun. 2000; 8:488–94.
Dumoutier L, Louahed J, Renauld JC. Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9. J Immunol. 2000; 164:1814–9.
Dudakov JA, Hanash AM, van den Brink MR. Interleukin-22: Immunobiology and Pathology. Annu Rev Immunol. 2015; 33:747–85.
Ye Wu, Jie Min, Chang Ge, Jinping Shu, Di Tian, Yuan Yuan, and Dian Zhou. Interleukin 22 in Liver Injury, Inflammation and Cancer. Int J Biol Sci. 2020; 13: 2405–2413.
Xie MH, Aggarwal S, Ho WH, Foster J, Zhang Z, Stinson J, et al.. Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2–4 and IL-22R. J. Biol. Chem.2000; 275:31335–31339.
Mashiko S, Bouguermouh S, Rubio M, Baba N, Bissonnette R, Sarfati M. Human mast cells are major IL-22 producers in patients with psoriasis and atopic dermatitis. J Allergy Clin Immunol. 2015; 136:351–9.e1.
Sabat R, Ouyang W, Wolk K. Therapeutic opportunities of the IL-22-IL-22R1 system. Nat Rev Drug Discov. 2014; 1:21–38.
Zhang X, Liu S, Wang Y, Hu H, Li L, Wu Y, et al.. Interleukin-22 regulates the homeostasis of the intestinal epithelium during inflammation. Int J Mol Med. 2019; 43:1657–68.
Patnaude L, Mayo M, Mario R, Wu X, Knight H, Creamer K, et al.. Mechanisms and regulation of IL-22-mediated intestinal epithelial homeostasis and repair. Life Sci. 2021; 271:119195.
Mihi B, Gong Q, Nolan LS, Gale SE, Goree M, Hu E, et al.. Interleukin-22 signaling attenuates necrotizing enterocolitis by promoting epithelial cell regeneration. Cell Rep Med. 2021; 2:100320.
Wolk K, Witte E, Hoffmann U, Doecke WD, Endesfelder S, Asadullah K, et al.. IL-22 induces lipopolysaccharide-binding protein in hepatocytes: a potential systemic role of IL-22 in Crohn's disease. J. Immunol. 2007; 178:5973–5981.
Wang X, Ota N, Manzanillo P, Kates L, Zavala-Solorio J, Eidenschenk C, et al.. Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes. Nature. 2014; 7521:237–41.
Mo R, Lai R, Lu J, Zhuang Y, Zhou T, Jiang S, et al.. Enhanced autophagy contributes to protective effects of IL-22 against acetaminophen-induced liver injury. Theranostics. 2018; 8:4170–80.
Fu X, Xiu Z, Xu H. Interleukin-22 and acute pancreatitis: A review. Medicine. 2023; 44:e35695.
John DS, Aschenbach J, Krüger B, et al.. Deficiency of cathepsin C ameliorates severity of AP by reduction of neutrophil elastase activation and cleavage of E-cadherin. J Biol Chem. 2019; 294:697–707
Vasseur P, Devaure I, Sellier J, Delwail A, Chagneau-Derrode C, Charier F, et al.. High plasma levels of the pro-inflammatory cytokine IL-22 and the anti-inflammatory cytokines IL-10 and IL-1ra in acute pancreatitis. Pancreatology. 2014; 14:465–9.
Zhang JL, Chen WD, Wang XY. Expression and significance of IL-22 in serum of patients with acute pancreatitis. J Hepatobiliary Surg. 2010; 29:214–6.
Xue J, Nguyen DT, Habtezion A. Aryl hydrocarbon receptor regulates pancreatic IL-22 production and protects mice from acute pancreatitis. Gastroenterology. 2012;143:1670–80.
Wang X, Ota N, Manzanillo P, Kates L, Zavala-Solorio J, Eidenschenk C, et al. Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes. Nature. 2014; 7521:237–41.
Huan C, Kim D, Ou P, Alfonso A, Stanek A. Mechanisms of interleukin-22’s beneficial effects in acute pancreatitis. World J Gastrointest Pathophysiol. 2016; 7:108–16.
Feng D, Park O, Radaeva S, Wang H, Yin S, Kong X, et al.. Interleukin-22 ameliorates Cerulein-induced pancreatitis in mice by inhibiting the autophagic pathway. Int J Biol Sci. 2012; 8:249–57.
McAleer JP, Kolls JK. Directing traffic: IL-17 and IL-22 coordinate pulmonary immune defense. Immunol Rev. 2014; 260:129–144.
Aujla SJ, Chan YR, Zheng M, Fei M, Askew DJ, Pociask DA, et al.. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med. 2008;14:275–281.
Besnard AG, Sabat R, Dumoutier L, Renauld J-C, Willart M, Lambrecht B, et al.. Dual Role of IL-22 in allergic airway inflammation and its cross-talk with IL-17A. Am. J. Respir. Crit. Care Med. 2011;183:1153–1163
Schnyder B, Lima C, Schnyder-Candrian S. Interleukin-22 is a negative regulator of the allergic response. Cytokine. 2010; 2:220–7.
Takahashi K, Hirose K, Kawashima S, Niwa Y, Wakashin H, Iwata A, et al. IL-22 attenuates IL-25 production by lung epithelial cells and inhibits antigen-induced eosinophilic airway inflammation. J Allergy Clin Immunol. 2011; 5:1067–76.
Van Maele L, Carnoy C, Cayet D, Ivanov S, Porte R, Deruy E, et al.. Activation of Type 3 innate lymphoid cells and interleukin 22 secretion in the lungs during Streptococcus pneumoniae infection. J Infect Dis. 2014; 210:493–503.
Xu X, Weiss ID, H HZ, Singh SP, Wynn TA, Wilson MS, et al.. Conventional NK Cells Can Produce IL-22 and Promote Host Defense in Klebsiella pneumoniae Pneumonia. J Immunol. 2014; 192:1778–1786.
Peng Y, Gao X, Yang J, Shekhar S, Wang S, Fan Y, et al.. IL-22 Promotes Th1/Th17 Immunity in Chlamydial Lung Infection. Mol Med. 2014
Simonian PL, Wehrmann F, Roark C-L, Born W-K, O'Brien R-L, Fontenot A-P. [gamma][delta] T cells protect against lung fibrosis via IL-22. J. Exp. Med. 2010; 207:2239–2253.
Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R. IL-22 increases the innate immunity of tissues. Immunity. 2004; 21:241–254.
Wolk K, Witte E, Wallace E, Döcke WD, Kunz S, Asadullah K, et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol. 2006; 5:1309–23.
Eyerich S, Wagener J, Wenzel V, Scarponi C, Pennino D, Albanesi C, et al. IL-22 and TNF-α represent a key cytokine combination for epidermal integrity during infection with Candida albicans. Eur J Immunol. 2011; 7:1894–901.
Van Belle AB, de Heusch M, Lemaire MM, Hendrickx E, Warnier G, Dunussi-Joannopoulos K, et al. IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice. J Immunol. 2012; 1:462–9.
Wolk K, Witte E, Wallace E, Döcke W‐D, Kunz S, Asadullah K, et al. IL‐22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol. 2006; 36:1309–23.
Nikamo P, Cheuk S, Lysell J, Enerbäck C, Bergh K, Xu Landén N, et al. Genetic variants of the IL22 promoter associate to onset of psoriasis before puberty and increased IL‐22 production in T cells. J Invest Dermatol. 2014; 134:1535–41.
Gittler JK, Shemer A, Suárez‐Fariñas M, Fuentes‐Duculan J, Gulewicz KJ, Wang CQF, et al. Progressive activation of TH2/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012;130:1344–54.
Guttman‐Yassky E, Nograles KE, Krueger JG. Contrasting pathogenesis of atopic dermatitis and psoriasis – Part II: immune cell subsets and therapeutic concepts. J Allergy Clin Immunol. 2011; 127:1420–32.
Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016; 1:6–15.
Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018; 3:364–79.
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus On diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004; 1:19–25.
Dumesic DA, Abbott DH, Sanchita S, Chazenbalk GD. Endocrine-metabolic dysfunction in polycystic ovary syndrome: an evolutionary perspective. Curr Opin Endocr Metab Res. 2020; 12:41–8.
Wang X, Ota N, Manzanillo P, Kates L, Zavala-Solorio J, Eidenschenk C, et al. Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes. Nature. 2014; 7521:237–41.
Hwang S, He Y, Xiang X, Seo W, Kim SJ, Ma J, et al. Interleukin-22 ameliorates neutrophil-driven nonalcoholic steatohepatitis through multiple targets. Hepatology. 2020; 2:412–29.
Qi X, Yun C, Sun L, Xia J, Wu Q, Wang Y, et al. Gut microbiota-bile acid-interleukin-22 axis orchestrates polycystic ovary syndrome. Nat Med. 2019;8:1225–33.
Luo M, Chen Y, Pan X, Chen H, Fan L, Wen YE. E. coli Nissle 1917 ameliorates mitochondrial injury of granulosa cells in polycystic ovary syndrome through promoting gut immune factor IL-22 via gut microbiota and microbial metabolism. Front Immunol. 2023;14:1137089.
Park O, Wang H, Weng H, Feigenbaum L, Li H, Yin S, et al. In vivo consequences of liver-specific interleukin-22 expression in mice: implications for human liver disease progression. Hepatology. 2011; 1:252–61.
Cella M, Fuchs A, Vermi W, Facchetti F, Otero K, Lennerz JK, et al.. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature. 2009;457:722–725.
Sommer A, Fabri M. Vitamin D regulates cytokine patterns secreted by dendritic cells to promote differentiation of IL‐22‐Producing T cells. PLoS One. 2015;10:1–22.
Lovato P, Norsgaard H, Tokura Y, Røpke MA. Calcipotriol and betamethasone dipropionate exert additive inhibitory effects on the cytokine expression of inflammatory dendritic cell‐Th17 cell axis in psoriasis. J Dermatol Sci. 2016;81:153–64.
Sugimoto K., Ogawa A., Mizoguchi E., Shimomura Y., Andoh A., Bhan A.K., et al.. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J. Clin. Invest. 2008; 118:534–544.
Turner J.E., Stockinger B., and Helmby H. IL-22 mediates goblet cell hyperplasia and worm expulsion in intestinal helminth infection. PLoS Pathog. 2013; 9:e1003698
Magalhães A., Gomes J., Ismail M.N., Haslam S.M., Mendes N., Osório H., et al.. Fut2-null mice display an altered glycosylation profile and impaired BabA-mediated Helicobacter pylori adhesion to gastric mucosa. Glycobiology. 2009; 19:1525–1536.
Pacheco A.R., Curtis M.M., Ritchie J.M., Munera D., Waldor M.K., Moreira C.G., et al.. Fucose sensing regulates bacterial intestinal colonization. Nature. 2012;492:113–117.
Muñoz M., Eidenschenk C., Ota N., Wong K., Lohmann U., Kühl A.A., et al.. Interleukin-22 induces interleukin-18 expression from epithelial cells during intestinal infection. Immunity. 2015; 42:321–331.
Sakamoto K., Kim Y.G., Hara H., Kamada N., Caballero-Flores G., Tolosano E., et al.. IL-22 Controls Iron-Dependent Nutritional Immunity Against Systemic Bacterial Infections. Sci. Immunol. 2017; 8:eaai8371
Hasegawa M., Yada S., Liu M.Z., Kamada N., Muñoz-Planillo R., Do N., et al.. Interleukin-22 regulates the complement system to promote resistance against pathobionts after pathogen-induced intestinal damage. Immunity. 2014; 41:620–632.
Ivanov S., Renneson J., Fontaine J., Barthelemy A., Paget C., Fernandez E.M., et al.. Interleukin-22 reduces lung inflammation during influenza A virus infection and protects against secondary bacterial infection. J. Virol. 2013; 87:6911–6924.
Jostins L., Ripke S., Weersma R.K., Duerr R.H., McGovern D.P., Hui K.Y., et al.. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012; 491:119–124.
Pelczar P., Witkowski M., Perez L.G., Kempski J., Hammel A.G., Brockmann L., et al.. A pathogenic role for T cell-derived IL-22BP in inflammatory bowel disease. Science. 2016; 354:358–362.
Dudakov J.A., Mertelsmann A.M., O’Connor M.H., Jenq R.R., Velardi E., Young L.F., et al.. Loss of thymic innate lymphoid cells leads to impaired thymopoiesis in experimental graft-versus-host disease. Blood. 2017; 130:933–942.
Gronke K., Hernández P.P., Zimmermann J., Klose C.S.N., Kofoed-Branzk M., Guendel F., et al.. Interleukin-22 protects intestinal stem cells against genotoxic stress. Nature. 2019; 566:249–253.
Kirchberger S., Royston D.J., Boulard O., Thornton E., Franchini F., Szabady R.L., et al.. Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. J. Exp. Med. 2013; 210:917–931.
Dumoutier L, Van Roost E, Ameye G, Michaux L, Renauld JC. IL-TIF/IL-22: genomic organization and mapping of the human and mouse genes. Genes Immun. 2000; 8:488–94.
Dumoutier L, Louahed J, Renauld JC. Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9. J Immunol. 2000; 164:1814–9.
Dudakov JA, Hanash AM, van den Brink MR. Interleukin-22: Immunobiology and Pathology. Annu Rev Immunol. 2015; 33:747–85.
Ye Wu, Jie Min, Chang Ge, Jinping Shu, Di Tian, Yuan Yuan, and Dian Zhou. Interleukin 22 in Liver Injury, Inflammation and Cancer. Int J Biol Sci. 2020; 13: 2405–2413.
Xie MH, Aggarwal S, Ho WH, Foster J, Zhang Z, Stinson J, et al.. Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2–4 and IL-22R. J. Biol. Chem.2000; 275:31335–31339.
Mashiko S, Bouguermouh S, Rubio M, Baba N, Bissonnette R, Sarfati M. Human mast cells are major IL-22 producers in patients with psoriasis and atopic dermatitis. J Allergy Clin Immunol. 2015; 136:351–9.e1.
Sabat R, Ouyang W, Wolk K. Therapeutic opportunities of the IL-22-IL-22R1 system. Nat Rev Drug Discov. 2014; 1:21–38.
Zhang X, Liu S, Wang Y, Hu H, Li L, Wu Y, et al.. Interleukin-22 regulates the homeostasis of the intestinal epithelium during inflammation. Int J Mol Med. 2019; 43:1657–68.
Patnaude L, Mayo M, Mario R, Wu X, Knight H, Creamer K, et al.. Mechanisms and regulation of IL-22-mediated intestinal epithelial homeostasis and repair. Life Sci. 2021; 271:119195.
Mihi B, Gong Q, Nolan LS, Gale SE, Goree M, Hu E, et al.. Interleukin-22 signaling attenuates necrotizing enterocolitis by promoting epithelial cell regeneration. Cell Rep Med. 2021; 2:100320.
Wolk K, Witte E, Hoffmann U, Doecke WD, Endesfelder S, Asadullah K, et al.. IL-22 induces lipopolysaccharide-binding protein in hepatocytes: a potential systemic role of IL-22 in Crohn's disease. J. Immunol. 2007; 178:5973–5981.
Wang X, Ota N, Manzanillo P, Kates L, Zavala-Solorio J, Eidenschenk C, et al.. Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes. Nature. 2014; 7521:237–41.
Mo R, Lai R, Lu J, Zhuang Y, Zhou T, Jiang S, et al.. Enhanced autophagy contributes to protective effects of IL-22 against acetaminophen-induced liver injury. Theranostics. 2018; 8:4170–80.
Fu X, Xiu Z, Xu H. Interleukin-22 and acute pancreatitis: A review. Medicine. 2023; 44:e35695.
John DS, Aschenbach J, Krüger B, et al.. Deficiency of cathepsin C ameliorates severity of AP by reduction of neutrophil elastase activation and cleavage of E-cadherin. J Biol Chem. 2019; 294:697–707
Vasseur P, Devaure I, Sellier J, Delwail A, Chagneau-Derrode C, Charier F, et al.. High plasma levels of the pro-inflammatory cytokine IL-22 and the anti-inflammatory cytokines IL-10 and IL-1ra in acute pancreatitis. Pancreatology. 2014; 14:465–9.
Zhang JL, Chen WD, Wang XY. Expression and significance of IL-22 in serum of patients with acute pancreatitis. J Hepatobiliary Surg. 2010; 29:214–6.
Xue J, Nguyen DT, Habtezion A. Aryl hydrocarbon receptor regulates pancreatic IL-22 production and protects mice from acute pancreatitis. Gastroenterology. 2012;143:1670–80.
Wang X, Ota N, Manzanillo P, Kates L, Zavala-Solorio J, Eidenschenk C, et al. Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes. Nature. 2014; 7521:237–41.
Huan C, Kim D, Ou P, Alfonso A, Stanek A. Mechanisms of interleukin-22’s beneficial effects in acute pancreatitis. World J Gastrointest Pathophysiol. 2016; 7:108–16.
Feng D, Park O, Radaeva S, Wang H, Yin S, Kong X, et al.. Interleukin-22 ameliorates Cerulein-induced pancreatitis in mice by inhibiting the autophagic pathway. Int J Biol Sci. 2012; 8:249–57.
McAleer JP, Kolls JK. Directing traffic: IL-17 and IL-22 coordinate pulmonary immune defense. Immunol Rev. 2014; 260:129–144.
Aujla SJ, Chan YR, Zheng M, Fei M, Askew DJ, Pociask DA, et al.. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med. 2008;14:275–281.
Besnard AG, Sabat R, Dumoutier L, Renauld J-C, Willart M, Lambrecht B, et al.. Dual Role of IL-22 in allergic airway inflammation and its cross-talk with IL-17A. Am. J. Respir. Crit. Care Med. 2011;183:1153–1163
Schnyder B, Lima C, Schnyder-Candrian S. Interleukin-22 is a negative regulator of the allergic response. Cytokine. 2010; 2:220–7.
Takahashi K, Hirose K, Kawashima S, Niwa Y, Wakashin H, Iwata A, et al. IL-22 attenuates IL-25 production by lung epithelial cells and inhibits antigen-induced eosinophilic airway inflammation. J Allergy Clin Immunol. 2011; 5:1067–76.
Van Maele L, Carnoy C, Cayet D, Ivanov S, Porte R, Deruy E, et al.. Activation of Type 3 innate lymphoid cells and interleukin 22 secretion in the lungs during Streptococcus pneumoniae infection. J Infect Dis. 2014; 210:493–503.
Xu X, Weiss ID, H HZ, Singh SP, Wynn TA, Wilson MS, et al.. Conventional NK Cells Can Produce IL-22 and Promote Host Defense in Klebsiella pneumoniae Pneumonia. J Immunol. 2014; 192:1778–1786.
Peng Y, Gao X, Yang J, Shekhar S, Wang S, Fan Y, et al.. IL-22 Promotes Th1/Th17 Immunity in Chlamydial Lung Infection. Mol Med. 2014
Simonian PL, Wehrmann F, Roark C-L, Born W-K, O'Brien R-L, Fontenot A-P. [gamma][delta] T cells protect against lung fibrosis via IL-22. J. Exp. Med. 2010; 207:2239–2253.
Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R. IL-22 increases the innate immunity of tissues. Immunity. 2004; 21:241–254.
Wolk K, Witte E, Wallace E, Döcke WD, Kunz S, Asadullah K, et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol. 2006; 5:1309–23.
Eyerich S, Wagener J, Wenzel V, Scarponi C, Pennino D, Albanesi C, et al. IL-22 and TNF-α represent a key cytokine combination for epidermal integrity during infection with Candida albicans. Eur J Immunol. 2011; 7:1894–901.
Van Belle AB, de Heusch M, Lemaire MM, Hendrickx E, Warnier G, Dunussi-Joannopoulos K, et al. IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice. J Immunol. 2012; 1:462–9.
Wolk K, Witte E, Wallace E, Döcke W‐D, Kunz S, Asadullah K, et al. IL‐22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol. 2006; 36:1309–23.
Nikamo P, Cheuk S, Lysell J, Enerbäck C, Bergh K, Xu Landén N, et al. Genetic variants of the IL22 promoter associate to onset of psoriasis before puberty and increased IL‐22 production in T cells. J Invest Dermatol. 2014; 134:1535–41.
Gittler JK, Shemer A, Suárez‐Fariñas M, Fuentes‐Duculan J, Gulewicz KJ, Wang CQF, et al. Progressive activation of TH2/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012;130:1344–54.
Guttman‐Yassky E, Nograles KE, Krueger JG. Contrasting pathogenesis of atopic dermatitis and psoriasis – Part II: immune cell subsets and therapeutic concepts. J Allergy Clin Immunol. 2011; 127:1420–32.
Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016; 1:6–15.
Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018; 3:364–79.
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus On diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004; 1:19–25.
Dumesic DA, Abbott DH, Sanchita S, Chazenbalk GD. Endocrine-metabolic dysfunction in polycystic ovary syndrome: an evolutionary perspective. Curr Opin Endocr Metab Res. 2020; 12:41–8.
Wang X, Ota N, Manzanillo P, Kates L, Zavala-Solorio J, Eidenschenk C, et al. Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes. Nature. 2014; 7521:237–41.
Hwang S, He Y, Xiang X, Seo W, Kim SJ, Ma J, et al. Interleukin-22 ameliorates neutrophil-driven nonalcoholic steatohepatitis through multiple targets. Hepatology. 2020; 2:412–29.
Qi X, Yun C, Sun L, Xia J, Wu Q, Wang Y, et al. Gut microbiota-bile acid-interleukin-22 axis orchestrates polycystic ovary syndrome. Nat Med. 2019;8:1225–33.
Luo M, Chen Y, Pan X, Chen H, Fan L, Wen YE. E. coli Nissle 1917 ameliorates mitochondrial injury of granulosa cells in polycystic ovary syndrome through promoting gut immune factor IL-22 via gut microbiota and microbial metabolism. Front Immunol. 2023;14:1137089.
Park O, Wang H, Weng H, Feigenbaum L, Li H, Yin S, et al. In vivo consequences of liver-specific interleukin-22 expression in mice: implications for human liver disease progression. Hepatology. 2011; 1:252–61.
Cella M, Fuchs A, Vermi W, Facchetti F, Otero K, Lennerz JK, et al.. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature. 2009;457:722–725.
Sommer A, Fabri M. Vitamin D regulates cytokine patterns secreted by dendritic cells to promote differentiation of IL‐22‐Producing T cells. PLoS One. 2015;10:1–22.
Lovato P, Norsgaard H, Tokura Y, Røpke MA. Calcipotriol and betamethasone dipropionate exert additive inhibitory effects on the cytokine expression of inflammatory dendritic cell‐Th17 cell axis in psoriasis. J Dermatol Sci. 2016;81:153–64.
Sugimoto K., Ogawa A., Mizoguchi E., Shimomura Y., Andoh A., Bhan A.K., et al.. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J. Clin. Invest. 2008; 118:534–544.
Turner J.E., Stockinger B., and Helmby H. IL-22 mediates goblet cell hyperplasia and worm expulsion in intestinal helminth infection. PLoS Pathog. 2013; 9:e1003698
Magalhães A., Gomes J., Ismail M.N., Haslam S.M., Mendes N., Osório H., et al.. Fut2-null mice display an altered glycosylation profile and impaired BabA-mediated Helicobacter pylori adhesion to gastric mucosa. Glycobiology. 2009; 19:1525–1536.
Pacheco A.R., Curtis M.M., Ritchie J.M., Munera D., Waldor M.K., Moreira C.G., et al.. Fucose sensing regulates bacterial intestinal colonization. Nature. 2012;492:113–117.
Muñoz M., Eidenschenk C., Ota N., Wong K., Lohmann U., Kühl A.A., et al.. Interleukin-22 induces interleukin-18 expression from epithelial cells during intestinal infection. Immunity. 2015; 42:321–331.
Sakamoto K., Kim Y.G., Hara H., Kamada N., Caballero-Flores G., Tolosano E., et al.. IL-22 Controls Iron-Dependent Nutritional Immunity Against Systemic Bacterial Infections. Sci. Immunol. 2017; 8:eaai8371
Hasegawa M., Yada S., Liu M.Z., Kamada N., Muñoz-Planillo R., Do N., et al.. Interleukin-22 regulates the complement system to promote resistance against pathobionts after pathogen-induced intestinal damage. Immunity. 2014; 41:620–632.
Ivanov S., Renneson J., Fontaine J., Barthelemy A., Paget C., Fernandez E.M., et al.. Interleukin-22 reduces lung inflammation during influenza A virus infection and protects against secondary bacterial infection. J. Virol. 2013; 87:6911–6924.
Jostins L., Ripke S., Weersma R.K., Duerr R.H., McGovern D.P., Hui K.Y., et al.. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012; 491:119–124.
Pelczar P., Witkowski M., Perez L.G., Kempski J., Hammel A.G., Brockmann L., et al.. A pathogenic role for T cell-derived IL-22BP in inflammatory bowel disease. Science. 2016; 354:358–362.
Dudakov J.A., Mertelsmann A.M., O’Connor M.H., Jenq R.R., Velardi E., Young L.F., et al.. Loss of thymic innate lymphoid cells leads to impaired thymopoiesis in experimental graft-versus-host disease. Blood. 2017; 130:933–942.
Gronke K., Hernández P.P., Zimmermann J., Klose C.S.N., Kofoed-Branzk M., Guendel F., et al.. Interleukin-22 protects intestinal stem cells against genotoxic stress. Nature. 2019; 566:249–253.
Kirchberger S., Royston D.J., Boulard O., Thornton E., Franchini F., Szabady R.L., et al.. Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. J. Exp. Med. 2013; 210:917–931.
Sayfalar
69-80
Gelecek
14 Ocak 2025
Telif Hakkı (c) 2025 Akademisyen Yayınevi Kitap DOI Portalı
